Company intelligence / Profile preview

AmpliMed Corporation

Tucson, Arizona, United Statesamplimed.com.br ↗

Ownership: Private
Development stage: Phase 1

Overview

AmpliMed's lead compound Amplimexon showed promising results in Phase I/II trials for metastatic melanoma. When combined with dacarbazine, patients with less advanced disease had a survival advantage of 11.7 months compared to approximately 8 months for dacarbazine-treated historical controls. The drug demonstrated relatively infrequent side effects even when administered with full-dose chemotherapy.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on AmpliMed Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmpliMed Corporation.

Explore the full profile